المصدر: Reactions Weekly; 3/30/2024, Vol. 2001 Issue 1, p35-35, 1p

مصطلحات موضوعية: HEMOPHAGOCYTIC lymphohistiocytosis, ANTINEOPLASTIC agents, FEVER, CONGENITAL disorders, DRUG side effects, LACTATE dehydrogenase

مستخلص: A 63-year-old man developed haemophagocytic lymphohistiocytosis (HLH) while being treated for metastatic melanoma with binimetinib, dabrafenib, encorafenib, and trametinib. After three months of treatment, he achieved a complete response, but five months later, he developed symptoms including fever, splenomegaly, and hepatic cytolysis. Laboratory tests and imaging confirmed a diagnosis of drug-induced HLH. The medications were discontinued, and HLH resolved, but when the man started a second-line therapy with encorafenib and binimetinib, HLH symptoms recurred. Treatment with corticosteroids was initiated, and HLH eventually resolved. [Extracted from the article]

: Copyright of Reactions Weekly is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المصدر: Reactions Weekly. Aug2018, Vol. 1713 Issue 1, p120-120. 1p.

مصطلحات موضوعية: *LACTATE dehydrogenase, *DRUG side effects

المصدر: Reactions Weekly; 2/3/2007, Issue 1137, p6-7, 2p

مصطلحات موضوعية: TUMORS, CANCER chemotherapy, CANCER chemoprevention, LACTATE dehydrogenase, DRUG side effects

مستخلص: The article presents a case study of a 67-year-old woman who developed tumor lysis syndrome characterized by extremely elevated lactate dehydrogenase and AST levels during her first cycle of bortezomib therapy for stage III multiple myeloma. Dexamethasone was included in the concomitant medications administered on the same days as bortezomib, prophylactic allopurinol and a disphosphonate regimen.

المصدر: Reactions Weekly; 9/26/2009, Issue 1271, p22-22, 1/5p

مصطلحات موضوعية: DISEASES in women, HEPATITIS, INFLIXIMAB, DRUG side effects, DRUG dosage, LACTATE dehydrogenase, AMINOTRANSFERASES

مستخلص: The article describes the case of a 38-year-old woman who developed toxic hepatitis while receiving treatment with infliximab for rheumatoid arthritis. Particular focus is given to the dosage of infliximab given to the woman. She experienced progressive elevations of lactate dehydrogenase and transaminases. Her condition improved following infliximab cessation. After several weeks, her liver enzymes were all within normal ranges.